6-(2-Carboxyethyl)-7-hydroxy-2,2-dimethyl-4-chromanone glucoside



Compound IDCDAMM01725
Common name6-(2-Carboxyethyl)-7-hydroxy-2,2-dimethyl-4-chromanone glucoside
IUPAC name3-[2,2-dimethyl-4-oxo-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3H-chromen-6-yl]propanoic acid
Molecular formulaC20H26O10

Experimental data

Retention time6.24
Adduct[M+H]+
Actual mz427.155
Theoretical mz427.16
Error12.35
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.1519

Identifiers and class information

Inchi keyDSNULGSRJZPYOC-UHFFFAOYNA-N
SmilesO=C(O)CCC=1C=C2C(=O)CC(OC2=CC1OC3OC(CO)C(O)C(O)C3O)(C)C
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)10
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)426.419
Computed dipole moment(dipole)7.616
Total solvent accessible surface area (SASA)661.539
Hydrophobic component of SASA (FOSA)347.29
Hydrophilic component of SASA (FISA)282.203
Pie component of the SASA (PISA)32.045
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1234.2
Number of hydrogen bond donors (donorHB)5
Number of hydrogen bond acceptors (accptHB)14
Free energy of solvation of dipole (dip^2/V)0.0469974
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0473214
Globularity descriptor (glob)0.841138
Predicted polarizability in cubic angstroms (QPpolrz)37.124
Predicted hexadecane/gas partition coefficient (QPlogPC16)13.03
Predicted octanol/gas partition coefficient (QPlogPoct)27.954
Predicted water/gas partition coefficient (QPlogPw)22.356
Predicted octanol/water partition coefficient (QPlogPo/w)-0.271
Predicted aqueous solubility (QPlogS)-2.517
Conformation-independent predicted aqueous solubility (CIQPlogS)-2.912
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-2.448
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)5.289
Predicted brain/blood partition coefficient (QPlogBB)-2.698
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)2.178
Predicted skin permeability, log Kp (QPlogKp)-5.648
PM3 calculated ionization potential (IP(ev))9.459
PM3 calculated electron affinity (EA(eV))0.655
Number of likely metabolic reactions (#metab)7
Prediction of binding to human serum albumin (QPlogKhsa)-1.001
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)38.304
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)180.15
Number of nitrogen and oxygen atoms (#NandO)10
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P29274ADORA2AAdenosine A2a receptorT77365SwissTargetPrediction
P04818TYMSThymidylate synthase (by homology)T98397SwissTargetPrediction
P06280GLAAlpha-galactosidase AT61339SEA
P13866SLC5A1Sodium/glucose cotransporter 1T54771SwissTargetPrediction
P34913EPHX2Epoxide hydrataseT35734SwissTargetPrediction
P18405SRD5A1Steroid 5-alpha-reductase 1T70309SwissTargetPrediction
P11511CYP19A1Cytochrome P450 19A1T13260SwissTargetPrediction
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
Q9NY91SLC5A4Low affinity sodium-glucose cotransporterT22583SwissTargetPrediction
P31639SLC5A2Sodium/glucose cotransporter 2T30085SwissTargetPrediction
P16109SELPP-selectinT10965SEA
P14151SELLLeukocyte adhesion molecule-1T60526SEA
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SwissTargetPrediction and SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SwissTargetPrediction and SEA
P60842EIF4A1Eukaryotic initiation factor 4A-IT86805SwissTargetPrediction
Q9HC29NOD2Nucleotide-binding oligomerization domain-containing protein 2T75643SwissTargetPrediction
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T77365DI0319Orthostatic hypotension[ICD-11: BA21]P29274ADORA2A
T77365DI0331Parkinsonism[ICD-11: 8A00]P29274ADORA2A
T77365DI0359Radionuclide imaging[ICD-11: N.A.]P29274ADORA2A
T98397DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P04818TYMS
T98397DI0395Stomach cancer[ICD-11: 2B72]P04818TYMS
T61339DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]P06280GLA
T54771DI0120Diabetes mellitus[ICD-11: 5A10]P13866SLC5A1
T54771DI0175Heart failure[ICD-11: BD10-BD1Z]P13866SLC5A1
T54771DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P13866SLC5A1
T35734DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P34913EPHX2
T35734DI0190Hypertension[ICD-11: BA00-BA04]P34913EPHX2
T70309DI0347Prostate disease[ICD-11: GA91]P18405SRD5A1
T13260DI0062Breast cancer[ICD-11: 2C60-2C6Y]P11511CYP19A1
T13260DI0108Cushing syndrome[ICD-11: 5A70]P11511CYP19A1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T22583DI0009Acute diabete complication[ICD-11: 5A2Y]Q9NY91SLC5A4
T22583DI0417Type 2 diabetes mellitus[ICD-11: 5A11]Q9NY91SLC5A4
T30085DI0120Diabetes mellitus[ICD-11: 5A10]P31639SLC5A2
T30085DI0175Heart failure[ICD-11: BD10-BD1Z]P31639SLC5A2
T30085DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P31639SLC5A2
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T86805DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P60842EIF4A1
T75643DI0120Diabetes mellitus[ICD-11: 5A10]Q9HC29NOD2
T75643DI0179Hepatitis virus infection[ICD-11: 1E50-1E51]Q9HC29NOD2
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025